Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission
 tomography (PET)/computed tomography (CT) works in patients with solid tumors. Fluorine F 18
 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a
 radioactive tag and injected into the body to help with imaging scans. PET/CT uses a scanner
 to make detailed, computerized pictures of areas inside the body. PET/CT with Fluorine F 18
 fluorthanatrace may allow more tumor cells to be found in patients with ovarian, fallopian
 tube, or primary peritoneal cancer.
PRIMARY OBJECTIVES:

 I. Evaluate fluorine F 18 fluorthanatrace ([18F]Fluorthanatrace) positron emission
 tomography/computed tomography (PET/CT) as an imaging biomarker of poly [ADP-ribose]
 polymerase (PARP)-1 activity in 3 cohorts of cancer patients: 1) ovarian, fallopian tube,
 primary peritoneal 2) breast cancer, and 3) non-ovarian, non-breast solid tumor.

 SECONDARY OBJECTIVES:

 I. Evaluate the safety of [18F]Fluorthanatrace. II. Correlate [18F]Fluorthanatrace uptake
 measures with BRCA mutation status. III. Correlate [18F]Fluorthanatrace uptake measures with
 poly [ADP-ribose] polymerase (PARP-1) activity in tumor tissue samples in patients who
 undergo biopsies.

 IV. Evaluate change in [18F]Fluorthanatrace uptake measures after therapy.

 OUTLINE:

 Patients receive fluorodeoxyglucose (FDG) intravenously (IV) and undergo FDG PET/CT scan over
 20-30 minutes if they have not already had one per standard of care. At least 20-24 hours
 later, patients receive fluorine F 18 fluorthanatrace IV and undergo fluorine F 18
 fluorthanatrace ([18F]FTT) PET/CT over 1 hour.

 After completion of study treatment, patients are followed up at 24 hours.
Inclusion Criteria:

 -  History of known or suspected solid tumor.

 -  At least one lesion >= 1.0 cm that is seen on standard imaging (e.g. computed
 tomography [CT], magnetic resonance imaging [MRI], ultrasound, fludeoxyglucose [FDG]
 PET/CT).

 Exclusion Criteria:

 -  Females who are pregnant or breast feeding at the time of screening will not be
 eligible for this study; a urine pregnancy test will be performed in women of
 child-bearing potential < 2 weeks prior to screening as standard of care.

 -  Inability to tolerate imaging procedures in the opinion of an investigator or treating
 physician.

 -  Any current medical condition, illness, or disorder as assessed by medical record
 review and/or self-reported that is considered by a physician investigator to be a
 condition that could compromise participant safety or successful participation in the
 study.